Research programme: viral infection therapies - Quigley Pharma

Drug Profile

Research programme: viral infection therapies - Quigley Pharma

Alternative Names: QR-435; QR-439; QR-441; QR-444; QR-446

Latest Information Update: 16 Jul 2009

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Quigley Pharma
  • Class
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Preclinical Herpes simplex virus infections; Influenza A virus infections; Severe acute respiratory syndrome

Most Recent Events

  • 16 Jul 2009 Preclinical development is ongoing in USA and United Kingdom
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top